Jubilant Pharmova News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Jubilant Pharmova Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Jubilant Pharmova Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news and updates on Jubilant Pharmova from all sources in a single place.

Jubilant Pharmova Ltd.

25 Dec 2025, 06:48PM

1074.60

0.75%

Company Update

Jubilant Pharmova Ltd - 530019 - Jubilant Biosys Limited, Wholly-Owned Subsidiary Of The Company Has Received …

BSE India

Jubilant Biosys Limited, wholly-owned subsidiary of the Company has received an Order passed by the Joint Commissioner confirming demand of GST, penalty and interest for the 3 Financial Years

pdf

Jubilant Pharmova Ltd.

05 Dec 2025

1074.60

0.75%

Company Update

Jubilant Pharmova Ltd - 530019 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And …

BSE India

Receipt of Adjudication Order by Deputy Commissioner of Commercial Taxes

pdf

Jubilant Pharmova Ltd.

02 Dec 2025

1074.60

0.75%

Company Update

Jubilant Pharmova Ltd - 530019 - Report On Special Window For Re-Lodgement Of Transfer Requests Of …

BSE India

Report on Special Window for Re-lodgement of Transfer Requests of Physical Shares

pdf

Jubilant Pharmova Ltd.

02 Dec 2025

1074.60

0.75%

Company Update

Jubilant Pharmova Ltd - 530019 - Appointment Of Mr. Daniel J. O'Connor As CEO Of Jubilant …

BSE India

Appointment of Mr. Daniel J. O'' Connor as CEO of Jubilant Therapeutics Inc.

pdf

Jubilant Pharmova Ltd.

28 Nov 2025

1074.60

0.75%

Company Update

Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Special window for re-lodgement and KYC Updation

pdf

Jubilant Pharmova Ltd.

08 Nov 2025

1074.60

0.75%

Company Update

Jubilant Pharmova Ltd - 530019 - Submission Of Communication Email Sent To Shareholders Whose Dividend(S) Remains …

BSE India

Submission of Communication Email sent to Shareholders whose Dividend(s) remains unpaid pursuant to "Saksham Niveshak-100 Days Campaign"

pdf

Jubilant Pharmova Ltd.

05 Nov 2025

1074.60

0.75%

Jubilant Pharmova

Buy: Jubilant Pharmova Ltd.

Recommendation Target

ICICI Direct

We continue to focus on Jubilant's flagship segments such as Radiopharmaceuticals, Allergy Immunotherapy, CDMO Sterile Injectables and Drug Discovery Services which together contribute ~53% of the sales and more than 90% of the EBITDA on the back of their high-margin profile. Their performances are also critical in order to achieve the management's aspirational target for FY30 - doubling of overall revenues (FY24 base),...